 |
antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA] |
|---|---|
| Trade Name | Gti-2040 |
| Orphan Indication | Renal cancer |
| USA Market Approval | USA |
| USA Designation Date | 2003-03-12 00:00:00 |
| Sponsor | Lorus Therapeutics, Inc;2 Meridan Road, M9W427; |
